Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) had its price target upped by analysts at Stifel Nicolaus from $38.00 to $52.00 in a research report issued on Wednesday. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 33.44% from the stock’s current price.

A number of other analysts also recently commented on the company. Maxim Group increased their price target on Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Leerink Swann reissued an “outperform” rating and issued a $43.00 target price on shares of Zeltiq Aesthetics in a research report on Wednesday, July 13th. Zacks Investment Research raised Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research report on Saturday, July 23rd. Brean Capital reissued a “buy” rating and issued a $35.00 target price on shares of Zeltiq Aesthetics in a research report on Tuesday, June 21st. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $35.00 target price (up from $27.00) on shares of Zeltiq Aesthetics in a research report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $39.89.

Analyst Recommendations for Zeltiq Aesthetics (NASDAQ:ZLTQ)

Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 38.97 on Wednesday. The stock’s 50 day moving average price is $37.50 and its 200-day moving average price is $30.52. Zeltiq Aesthetics has a 12-month low of $18.41 and a 12-month high of $40.98. The firm has a market cap of $1.54 billion, a PE ratio of 58.60 and a beta of 0.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zeltiq-aesthetics-inc-zltq-price-target-raised-to-52-00.html

Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The business had revenue of $89.50 million for the quarter, compared to analysts’ expectations of $79.68 million. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 earnings per share. Equities research analysts anticipate that Zeltiq Aesthetics will post ($0.13) earnings per share for the current fiscal year.

In related news, Director Andrew N. Schiff sold 500,000 shares of Zeltiq Aesthetics stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $36.39, for a total transaction of $18,195,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keith J. Sullivan sold 8,000 shares of Zeltiq Aesthetics stock in a transaction on Monday, July 11th. The shares were sold at an average price of $30.02, for a total value of $240,160.00. Following the sale, the insider now directly owns 77,922 shares of the company’s stock, valued at approximately $2,339,218.44. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company’s stock.

Large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock valued at $116,913,000 after buying an additional 1,332,129 shares in the last quarter. Eagle Asset Management raised its stake in Zeltiq Aesthetics by 71.9% in the third quarter. Eagle Asset Management now owns 3,227,128 shares of the company’s stock valued at $103,364,000 after buying an additional 1,350,063 shares in the last quarter. Visium Asset Management LP raised its stake in Zeltiq Aesthetics by 95.2% in the fourth quarter. Visium Asset Management LP now owns 2,448,867 shares of the company’s stock valued at $69,867,000 after buying an additional 1,194,581 shares in the last quarter. BlackRock Fund Advisors raised its stake in Zeltiq Aesthetics by 9.5% in the second quarter. BlackRock Fund Advisors now owns 2,297,982 shares of the company’s stock valued at $62,804,000 after buying an additional 199,946 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Zeltiq Aesthetics by 30.7% in the second quarter. Point72 Asset Management L.P. now owns 2,219,762 shares of the company’s stock valued at $60,666,000 after buying an additional 521,462 shares in the last quarter.

About Zeltiq Aesthetics

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.